STOCK TITAN

Alterity Therapeutics Limited American Depositary Shares - $ATHE STOCK NEWS

Welcome to our dedicated page for Alterity Therapeutics American Depositary Shares news (Ticker: $ATHE), a resource for investors and traders seeking the latest updates and insights on Alterity Therapeutics American Depositary Shares stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alterity Therapeutics American Depositary Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alterity Therapeutics American Depositary Shares's position in the market.

Rhea-AI Summary
Alterity Therapeutics has received a A$4.74 million cash refund from the Australian Taxation Office under the Australian Government’s Research and Development Tax Incentive Scheme. The refund relates to eligible research and development activities conducted in the financial year ended 30 June 2022. The funds will be used for Alterity's clinical development and research activities, including Phase 2 clinical trials for ATH434 in Multiple System Atrophy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.1%
Tags
none
-
Rhea-AI Summary
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) releases Appendix 4C Quarterly Cash Flow Report and updates on company activities. The ATH434-201 Phase 2 study is on track to complete enrollment in Q3 2023, with top-line data expected by the end of 2024, while ATH434-202 Phase 2 Biomarker study is initiated. Promising wearable sensor data from the bioMUSE Natural History Study was presented at the AAN Annual Meeting. The cash balance on 30 June 2023 was $15.8M.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
none
-
Rhea-AI Summary
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced that the ATH434-201 Phase 2 study for the treatment of multiple system atrophy (MSA) will continue as planned. The study is on track to complete enrollment in Q3 2023, with top-line data expected by the end of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.5%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.38%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.51%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.38%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.38%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.06%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.82%
Tags
Alterity Therapeutics Limited American Depositary Shares

Nasdaq:ATHE

ATHE Rankings

ATHE Stock Data

17.46M
2.54B
1%
0.26%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Melbourne

About ATHE

alterity therapeutics limited researches and develops therapeutic drugs for the treatment of parkinsonian's disease and other neurodegenerative diseases in australia. the company's lead drug candidates is ath434 that has completed phase i clinical trial for the treatment of parkinson's disease. it is also developing pbt2 for used as an antimicrobial agent. the company was formerly known as prana biotechnology limited and changed its name to alterity therapeutics limited in april 2019. the company was founded in 1997 and is based in melbourne, australia.